Magic™ Anti-V5 tag antibody, clone TW6-Ql2 [AP]

Brain-derived neurotrophic factor (BDNF) is a protein with a potent influence on several aspects of neuronal and blood vessel functions. However, its prognostic potential and functional role in multiple myeloma (MM) remain largely unknown. In this study, we investigated the influence of BDNF on the risk of chemotherapy-induced peripheral neuropathy (CIPN) and clinical outcome. Study group consisted of 91 newly-diagnosed MM patients treated with bortezomib and/or thalidomide-based chemotherapy. Detection of BDNF in serum was performed using ELISA. Polyneuropathy was assessed according to the CTCAE Criteria v5. We observed that BDNF concentration correlated with the severity of polyneuropathy (P = 0 center dot 0463). Higher BDNF values were noted in patients who responded to treatment (P = 0 center dot 0326), and BDNF proved to be a useful marker to predict lack of response after eight cycles of treatment (sensitivity - 100%, specificity - 61 center dot 5%,P = 0 center dot 0142). Moreover this marker showed significant diagnostic usefulness in diagnosis of CIPN (sensitivity - 76%, specificity - 71 center dot 43%; area under the curve (AUC)= 0 center dot 77, 95%, confidence interval (CI): 0 center dot 64-0 center dot 88;P < 0 center dot 0001). Low BDNF was an independent, unfavourable prognostic factor associated with reduced overall survival (OS) (hazard ratio (HR) = 2 center dot 79,P = 0 center dot 0470). In conclusion, BDNF level may play a prognostic role and constitute a useful biomarker in predicting CIPN in MM patients.

Observers report seeing as slower a target disk moving in front of a static visual noise (SVN) background than the same object moving in front of a random dynamic visual noise (rDVN) background when the speed is the same. To investigate in which brain region (lower vs. higher visual areas) the background and the target signals might be combined to elicit this misperception, the transcranial magnetic stimulation (TMS) was delivered over the early visual cortex (V1/V2), middle temporal area (MT) and Cz (control site) while participants performed a speed discrimination task with targets moving in front of an SVN or an rDVN. Results showed that the TMS over MT reduced the perceived speed of the target moving in front of an SVN, but not when the target was moving in front of an rDVN background. Moreover, the TMS do not seem to interfere with encoding processing but more likely affected decoding processing in conditions of high uncertainty (i.e., when targets have similar speed).